DNA methylation and cancer therapy: New developments and expectations

Current Opinion in Oncology

Volumn 17, Issue 1, 2005, Pages 55-60

  Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

5 aza 2 deoxycytidine; 5 azacytidine; DNA methylation; DNA demethylating drugs; Myelodysplastic syndrome; Procaine; Tumor suppressor genes; Zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' AMINO 5' DEOXYADENOSINE; 5,6 DIHYDROAZACITIDINE; 6 AZACYTIDINE; AZACITIDINE; CISPLATIN; CYTARABINE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE; DIHYDOXYPROPYLADENINE; DNA DEMETHYLATING AGENT; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; ENZYME INHIBITOR; EPIGALLOCATHECHIN 3 GALLATE; ETHIONINE; FAZARABINE; FLUCYTOSINE DEOXYRIBOSIDE; HYDRALAZINE; NATURAL PRODUCT; NUCLEOSIDE ANALOG; POLYPHENOL DERIVATIVE; PROCAINAMIDE; PROCAINE; PSAMMAPLIN; PSEUDOISOCYTIDINE; S ADENOSYLMETHIONINE; SINEFUNGIN; UNCLASSIFIED DRUG; ZEBULARINE;

BONE MARROW SUPPRESSION; CANCER; CANCER THERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CPG ISLAND; CYTOTOXICITY; DNA METHYLATION; DRUG SPECIFICITY; ENZYME INACTIVATION; GENE INACTIVATION; HEART ARRHYTHMIA; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS;

EID: 13144251125     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000147383.04709.10     Document Type: Review

References (59)

1. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
2. Esteller M, Corn PG, Baylin SB, et al.: A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-3229.
3. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
4. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
5. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
6. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
7. Chen RZ, Pettersson U, Beard C, et al.: DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:199889-199893.
8. Eden A, Gaudet F, Waghmare A, et al.: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455. In a mouse model, the presence of hypomorphic alleles of DNMT1 is associated with the development of lymphomas and chromosomal instability.
9. Espada J, Ballestar E, Fraga MF, et al.: Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004, Jun 25. This article shows that cancer cells deficient in DNMT1 present aberrant nuclear structures.
10. Leone G, Voso MT, Teofili L, et al.: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003, 109:89-102.
11. Villar-Garea A, Esteller M: DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr Drug Metab 2003, 4:11-31.
12. Rhee I, Bachman KE, Park BH, et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
13. Paz MF, Wei S, Cigudosa JC, et al.: Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003, 12:2209-2219. This article demonstrates that the double inactivation of DNMT1 and DNMT3b induces a massive reactivation of previously dormant methylated tumor-suppressor genes.
14. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
15. Li LH, Olin EJ, Buskirk HH, et al.: Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970, 30:2760-2769.
16. Ho DH: Distribution of kinase and deaminase of 1-beta-D- arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973, 33:2816-2820.
17. Rivard GE, Momparler RL, Demers J, et al.: Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981, 5:453-462.
18. Driscoll JS, Marquez VE, Plowman J, et al.: Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 1991, 34:3280-3284.
19. Zhou L, Cheng X, Connolly BA, et al.: Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002, 321:591-599.
20. Cheng JC, Weisenberger DJ, Gonzales FA, et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004, 24:1270-1278. It shows that the combination of 5-aza-2′-deoxycytidine and zebularine is highly effective in maintaining the demethylation status of a tumor-suppressor gene.
21. Cheng JC, Matsen CB, Gonzales FA, et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003, 95:399-409. The first study showing the use of an oral DNA demethylating agent that restores the methylation of a tumor-suppressor gene and has antitumoral effects.
22. Cornacchia E, Golbus J, Maybaum J, et al.: Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988, 140:2197-2200.
23. Lin X, Asgari K, Putzi MJ, et al.: Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res 2001, 61:8611-8616.
24. Thomas TJ, Messner RP: Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthritis Rheum 1986, 29:638-645.
25. Villar-Garea A, Fraga MF, Espada J, et al.: Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003, 63:4984-4989. The first demonstration that the local anesthetic drug procaine also has DNA demethylation and antitumoral activities.
26. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al.: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003, 9:1596-1603. A new study pinpoints the DNA demethylating capacity of the old drug hydralazine.
27. Fang MZ, Wang Y, Ai N, et al.: Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003, 63:7563-7570. The first demonstration that these compounds may be able to reactivate hypermethylated tumor-suppressor genes.
28. Pina IC, Gautschi JT, Wang GY, et al.: Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003, 68:3866-3873. The first evidence of the DNA demethylation capacity of these compounds.
29. Esteller M, Fraga MF, Guo M, et al.: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001, 10:3001-3007.
30. Machado JC, Oliveira C, Carvalho R, et al.: E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001, 20:1525-1528.
31. Herman JG, Umar A, Polyak K, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998, 95:6870-6875.
32. Esteller M, Cordon-Cardo C, Corn PG, et al.: p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001, 61:2816-2821.
33. Paz MF, Fraga MF, Avila S, et al.: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003, 63:1114-1121. A study that shows that all cancer cell lines are sensitive to the DNA-demethylating effect of 5-aza-2′-deoxycytidine.
34. Nieto M, Samper E, Fraga MF, et al.: The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 2004, 23:735-743.
35. Laird PW, Jackson-Grusby L, Fazeli A, et al.: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81:197-205.
36. Yang AS, Estecio MR, Garcia-Manero G, et al.: Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science 2003, 302:1153.
37. Lubbert M, Wijermans P, Kunzmann R, et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2"-deoxycytidine. Br J Haematol 2001, 114:349-357.
38. Fraga MF, Herranz M, Espada J, et al.: A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004, 64:5527-5534. The first demonstration that there is a progressive loss of 5-methylcytosine DNA content in tumorigenesis.
39. Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4:13-18.
40. Richon VM, Zhou X, Secrist JP, et al.: Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. Methods Enzymol 2004, 376:199-205.
41. Villar-Garea A, Esteller M: Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer, in press.
42. Cameron EE, Bachman KE, Myohanen S, et al.: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
43. Soengas MS, Capodieci P, Polsky D, et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
44. Zhu WG, Dai Z, Ding H, et al.: Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 2001, 20:7787-7796.
45. Xiao J, Chen HS: Biological functions of melanoma-associated antigens. World J Gastroenterol 2004, 10:1849-1853.
46. Sekigawa I, Okada M, Ogasawara H, et al.: DNA methylation in systemic lupus erythematosus. Lupus 2003, 12:79-85.
47. Momparler RL, Bouffard DY, Momparler LF, et al.: Pilot phase I-II study on 5-aza-2"-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8:358-368.
48. Pohlmann P, DiLeone LP, Cancella AI, et al.: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002, 25:496-501.
49. Pinto A, Zagonel V, Attadia V, et al.: 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989, 4(suppl 3):28-32.
50. Wijermans P, Lubbert M, Verhoef G, et al.: Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956-962.
51. Wijermans PW, Luebbert M, Verhoef G: Low dose decitabine for elderly high risk MDS patients: who will respond? Blood 2002, 100:96a.
52. Issa JP, Garcia-Manero G, Giles FJ, et al.: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640. A study that proves that low doses of 5-aza-2′- deoxycytidine are effective in myeloid malignancies.
53. van den Bosch J, Lubbert M, Verhoef G, et al.: The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004, 28:785-790. 5-aza-2′-deoxycytidine affects platelet response and overall survival in myelodysplastic syndrome.
54. Silverman LR, Holland JF, Weinberg RS, et al.: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993, 7(suppl 1):21-29.
55. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
56. Camacho LH, Ryan HJ, Chanel P, et al.: Transcription modulation: a pilot study of sodium phenylbutyrate plus 5-azacytidine. Blood 2001, 98(suppl 1):460.
57. Daskalakis M, Nguyen TT, Nguyen C, et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
58. Fraga MF, Uriol E, Borja Diego L, et al.: High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 2002, 23:1677-1681.
59. Paz MF, Avila S, Fraga MF, et al.: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002, 62:4519-4524.